changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
BTG believes interventional medicine is the place to be. We are at the forefront today and committed to research that will keep us at the forefront tomorrow.
A message from Louise Makin, BTG CEO
6 things everyone should know about BTG IM
Our products are used in minimally invasive procedures to treat people with various types of cancer, arteriovenous malformation and to provide palliative intervention targeting diseased cells while decreasing the impact on healthy tissue.
For 10 years, we have been focussed on developing minimally-invasive medical devices for pulmonary diseases such as emphysema.
BTG helps interventional vascular teams solve problems with patients’ blood transport systems through evidence-based innovations that treat smarter and achieve more.
TheraSphere® yields tumor necrosis using radiation as the primary mechanism of action, with a microembolic effect.1,6
LC Bead® is a controlled embolization system intended for the purpose of embolizing the blood vessels of a variety of hypervascularized tumors and arteriovenous malformations. LC Bead® is a preformed, deformable microsphere consisting of a biocompatible, sulphonate-modified, N-Fil hydrogel.
Your choice for a controlled distal embolization.
Distal embolization may result in:
Proximal embolization may result in:
LC Bead LUMI™ is the first commercially available radiopaque embolic bead for the embolization of hypervascular tumors and arteriovenous malformations in the US.
The unique structure of Bead Block™ - PVA hydrogel crosslinked with acrylic polymer - ensures smooth delivery and targeted, effective embolization, while resisting attrition, fragmentation and aggregation.12, 13
GALIL™, a leading provider of cryoablation products for the treatment of kidney and other cancers provides clinicians with a broad product portfolio, supported by robust clinical data, to treat a wide range of diseases.
The emerging area of Interventional Pulmonology is dedicated to improving the lung function, exercise capacity and quality of life for patients with degraded lung function, including emphysema.5
Varithena® is the first and only FDA-approved foam for GSV system incompetence. It treats a wide range of vein anatomies and diameters above and below the knee.4,11
EKOS™ is setting the standard for PE treatment safety and efficacy, again. With the EKOS™ treatment’s successful very-low dose and short duration regimens in the OPTALYSE PE trial and favorable long term data results point to a paradigm-changing approach for PE treatment.
LC Bead LUMI™, the first radiopaque embolic bead
LC Bead® on Balancing Act
EKOS® Catheter Treatment of Massive & Sub-Massive Pulmonary Emboli
Synergy: A Multidisciplanary Approach to...
The VEINS at VIVA
VIVA - Vascular Interventional Advances
BTG to invest in Chinese medical...
NCCN issues first pediatric acute lympho...
Radioembolization treatment for primary ...
One-year results of ACCESS PTS study bri...
OPTALYSE PE Results Presented at Society...
Health Canada approves radiopaque bead f...